bullish
Venus Medtech IPO: First Mover Advantage in Chinese TAVR Market to Support Growth
626 Views12 Aug 2019 14:59
Venus Medtech is a leading transcatheter heart valve medical device maker based in China. It is the first company to obtain CFDA approval for...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 13-minute read)
Discussions
(Paid Plans Only)
- ZTO Express Secondary: Overvalued and More Expensive than Global Delivery Giants18 Sep 2020
- Genor Biopharma IPO: Strong Clinical Pipeline with Some Potential Blockbusters17 Sep 2020
- Venus Medtech IPO: Fairly Valued and More Room for Share Price to Grow27 Nov 2019
- Venus Medtech IPO: First Mover Advantage in Chinese TAVR Market to Support Growth12 Aug 2019
- Adaptive Biotechnologies IPO: Immune to Grow and Succeed; and the Future Looks Good24 Jun 2019
- Personalis IPO: Personalising Cancer Trials and Treatments; Upside from Growth in Cancer Market18 Jun 2019
x